www.fdanews.com/articles/204224-novartis-to-supply-leqvio-to-the-uks-national-health-service
![Novartis building](https://www.fdanews.com/ext/resources/test/Drug-Images/Novartis-buliding.gif?t=1614205171&width=430)
Novartis to Supply Leqvio to the UK’s National Health Service
September 2, 2021
Novartis has reached an agreement with the UK’s National Health Service to offer its potential blockbuster cholesterol-lowering drug Leqvio (inclisiran) for an undisclosed price.
The deal, which followed a cost-benefit review by the UK’s National Institute for Health and Care Excellence, will enable approximately 300,000 patients at high risk of a second cardiovascular event to be treated over three years.
Leqvio (inclisiran) is given as a 6-month maintenance dose for individuals with elevated low-density lipoprotein cholesterol who do not show an adequate response to statins.